Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Prostate Cancer

  Free Subscription


23.11.2020

3 AJR Am J Roentgenol
2 BJU Int
2 Clin Cancer Res
1 Curr Treat Options Oncol
2 Eur Radiol
3 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Lab Anal
1 J Nucl Med
12 J Urol
1 JAMA
2 Oncogene
1 Oncol Rep
1 Oncology (Williston Park)
1 Prog Urol
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. MA HY, Ahmed FS, Luk L, Martina LAP, et al
    The Negative Predictive Value of a PI-RADS Version 2 Score of 1 on Prostate MRI and the Factors Associated With a False-Negative MRI Study.
    AJR Am J Roentgenol. 2020 Jul 1:1-6. doi: 10.2214/AJR.20.22784.
    PubMed         Abstract available

  2. SHIN N, Park SY
    Postoperative Biochemical Failure in Patients With PI-RADS Category 4 or 5 Prostate Cancers: Risk Stratification According to Zonal Location of an Index Lesion.
    AJR Am J Roentgenol. 2020;215:913-919.
    PubMed         Abstract available

  3. SAVIR-BARUCH B, Choyke PL, Rowe SP, Schuster DM, et al
    Role of (18)F-Fluciclovine and Prostate-Specific Membrane Antigen PET/CT in Guiding Oligometastatic Prostate Cancer Management: AJR Expert Panel Narrative Review.
    AJR Am J Roentgenol. 2020 Nov 18. doi: 10.2214/AJR.20.24711.
    PubMed         Abstract available


    BJU Int

  4. NORRIS JM, Carmona Echeverria LM, Simpson BS, Ball R, et al
    Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out.
    BJU Int. 2020 Nov 13. doi: 10.1111/bju.15295.
    PubMed         Abstract available

  5. EGEVAD L, Delahunt B, Bostwick DG, Cheng L, et al
    Prostate Cancer Grading, Time To Go Back To the Future.
    BJU Int. 2020 Nov 18. doi: 10.1111/bju.15298.
    PubMed         Abstract available


    Clin Cancer Res

  6. LOTAN TL, Antonarakis ES
    CDK12 Deficiency and the Immune Microenvironment in Prostate Cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3877.
    PubMed         Abstract available

  7. DELUCIA DC, Cardillo TM, Ang LS, Labrecque MP, et al
    Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3396.
    PubMed         Abstract available


    Curr Treat Options Oncol

  8. FLEMING CW, Broughman JR, Tendulkar RD
    Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box.
    Curr Treat Options Oncol. 2020;22:2.
    PubMed         Abstract available


    Eur Radiol

  9. SVIRYDENKA H, Muehlematter UJ, Nagel HW, Delso G, et al
    (68)Ga-PSMA-11 dose reduction for dedicated pelvic imaging with simultaneous PET/MR using TOF BSREM reconstructions.
    Eur Radiol. 2020;30:3188-3197.
    PubMed         Abstract available

  10. CAGLIC I, Sushentsev N, Gnanapragasam VJ, Sala E, et al
    MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance.
    Eur Radiol. 2020 Nov 16. pii: 10.1007/s00330-020-07336.
    PubMed         Abstract available


    Eur Urol

  11. DE WIT R, Tombal B, Freedland S
    Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30805.
    PubMed         Abstract available

  12. DA SILVA FC, Algaba F
    Re: Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.
    Eur Urol. 2020 Nov 17. pii: S0302-2838(20)30852.
    PubMed        

  13. EPSTEIN JI, Kryvenko ON
    A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines.
    Eur Urol. 2020 Nov 11. pii: S0302-2838(20)30853.
    PubMed         Abstract available


    Int J Cancer

  14. GEORGE G, Garmo H, Scailteux LM, Balusson F, et al
    Risk of cardiovascular disease following GnRH agonists versus antagonists in prostate cancer: Real-world evidence from five databases.
    Int J Cancer. 2020 Nov 13. doi: 10.1002/ijc.33397.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  15. TAKAGI M, Demizu Y, Fujii O, D KT, et al
    Proton Therapy for Localized Prostate Cancer: Long-term Results in 2,021 Patients.
    Int J Radiat Oncol Biol Phys. 2020 Nov 10. pii: S0360-3016(20)34493.
    PubMed         Abstract available


    J Clin Lab Anal

  16. LI Z, Teng J, Jia Z, Zhang G, et al
    The long non-coding RNA PCAL7 promotes prostate cancer by strengthening androgen receptor signaling.
    J Clin Lab Anal. 2020 Nov 21:e23645. doi: 10.1002/jcla.23645.
    PubMed         Abstract available


    J Nucl Med

  17. CHANTADISAI M, Buschner G, Kronke M, Rauscher I, et al
    Positive predictive value and correct detection rate of (18)F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard.
    J Nucl Med. 2020 Nov 13. pii: jnumed.120.255661. doi: 10.2967/jnumed.120.255661.
    PubMed         Abstract available


    J Urol

  18. MONAGHAN TF, Weiss JP, Wein AJ
    Re: Impact of Nocturia on Mortality: The Nagahama StudyS. Funada, Y. Tabara, K. Setoh, H. Negoro, S. Akamatsu, T. Yoshino, K. Yoshimura, N. Watanabe, T. A. Furukawa, F. Matsuda and O. Ogawa J Urol 2020; doi: 10.1097/JU.0000000000001138.
    J Urol. 2020;204:1067-1068.
    PubMed        

  19. JAZAYERI SB, Balaji KC
    Re: Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-AnalysisA. Pilatz, K. Dimitropoulos, R. Veeratterapillay, Y. Yuan, M. I. Omar, S. MacLennan, T. Cai, F. Bruyere, R. Barto
    J Urol. 2020;204:1349-1350.
    PubMed        

  20. ATALA A
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-Cell Analysis.
    J Urol. 2020;204:1384.
    PubMed        

  21. MORASH C
    Editorial Comment.
    J Urol. 2020;204:1221.
    PubMed        

  22. STONIER T, Tin AL, Sjoberg DD, Jibara G, et al
    Selecting Patients with Favourable-Risk, GG2 Prostate Cancer for Active Surveillance: Does MRI Have a Role?
    J Urol. 2020 Nov 20:101097JU0000000000001519. doi: 10.1097/JU.0000000000001519.
    PubMed         Abstract available

  23. CHEN M, Zhuang J, Fu Y, Guo S, et al
    Can (68)Ga-PSMA-11 PET/CT Predict Pathologic Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy: A Pilot Study.
    J Urol. 2020 Nov 18:101097JU0000000000001481. doi: 10.1097/JU.0000000000001481.
    PubMed         Abstract available

  24. MEIJER D, Luiting HB, van Leeuwen PJ, Remmers S, et al
    PSMA PET/CT in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
    J Urol. 2020 Nov 18:101097JU0000000000001437. doi: 10.1097/JU.0000000000001437.
    PubMed         Abstract available

  25. KHOO CC, Eldred-Evans D, Peters M, van Son M, et al
    A Comparison of Prostate Cancer Detection Between Visual-Estimation (Cognitive Registration) and Image-Fusion (Software Registration) Targeted Transperineal Prostate Biopsy.
    J Urol. 2020 Nov 18:101097JU0000000000001476. doi: 10.1097/JU.0000000000001476.
    PubMed         Abstract available

  26. WIBMER AG, Chaim J, Lakhman Y, Lefkowitz R, et al
    Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pre-treatment Prostate MRI Findings.
    J Urol. 2020 Nov 18:101097JU0000000000001474. doi: 10.1097/JU.0000000000001474.
    PubMed         Abstract available

  27. DALL'ERA MA
    Editorial Comment.
    J Urol. 2020;204:1194.
    PubMed        

  28. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Nov 17:101097JU0000000000001501. doi: 10.1097/JU.0000000000001501.
    PubMed        

  29. EHDAIE B
    Editorial Comment.
    J Urol. 2020;204:1234-1235.
    PubMed        


    JAMA

  30. ALDUBAYAN SH, Conway JR, Camp SY, Witkowski L, et al
    Detection of Pathogenic Variants With Germline Genetic Testing Using Deep Learning vs Standard Methods in Patients With Prostate Cancer and Melanoma.
    JAMA. 2020;324:1957-1969.
    PubMed         Abstract available


    Oncogene

  31. SINGH KB, Hahm ER, Kim SH, Wendell SG, et al
    A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer.
    Oncogene. 2020 Nov 16. pii: 10.1038/s41388-020-01553.
    PubMed         Abstract available

  32. BUCKUP M, Rice MA, Hsu EC, Garcia-Marques F, et al
    Plectin is a regulator of prostate cancer growth and metastasis.
    Oncogene. 2020 Nov 20. pii: 10.1038/s41388-020-01557.
    PubMed         Abstract available


    Oncol Rep

  33. NOGUCHI M, Fujimoto K, Arai G, Uemura H, et al
    A randomized phase III trial of personalized peptide vaccination for castrationresistant prostate cancer progressing after docetaxel.
    Oncol Rep. 2020 Nov 11. doi: 10.3892/or.2020.7847.
    PubMed         Abstract available


    Oncology (Williston Park)

  34. BRODERICK JM
    Incidence of Metastatic Prostate Cancer On the Rise.
    Oncology (Williston Park). 2020;34:460.
    PubMed        


    Prog Urol

  35. VESVAL Q, Fiard G, Villers A, Norris JM, et al
    Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature.
    Prog Urol. 2020 Nov 11. pii: S1166-7087(20)30603.
    PubMed         Abstract available


    Urology

  36. BHATTU AS, Zappala SM, Parekh DJ, Punnen S, et al
    A 4Kscore cut-off of 7.5% for prostate biopsy decisions provides high sensitivity and negative predictive value for significant prostate cancer.
    Urology. 2020 Nov 17. pii: S0090-4295(20)31371.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: